Cardiovascular devices are used in treating diseases related to the heart and the circulatory system. Cardiac Rhythm Management (CRM) devices are those devices which are used to restore the natural synchronized pumping rhythm of the heart. Cardiac Resynchronization Therapy (CRT) is a device used for the treatment of heart failure-induced conduction disturbances and ventricular dyssynchrony. GlobalData uses proprietary data and analytics to provide a comprehensive report on the cardiac resynchronisation therapy devices market, including market shares of different players within New Zealand. Buy the latest report here.
Smarter leaders trust GlobalData
In 2022, GlobalData’s Market Model methodology determined that the leading player in the cardiac resynchronisation therapy market in New Zealand was Abbott Laboratories followed by Medtronic, Boston Scientific, Biotronik SE and MicroPort Scientific.
When used in combination with stable, optimal medical therapy, CRT is designed to reduce symptoms and improve cardiac function by restoring the mechanical sequence of ventricular activation and contraction. Cardiac Resynchronization Therapy – Defibrillator uses an Implantable Cardioverter Defibrillator (ICD) to improve the coordination of the heart rhythm. Cardiac Resynchronization Therapy – Pacemaker uses a pacemaker device to improve the coordination of the heart rhythm. Wireless – Cardiac resynchronization therapy uses a leadless pacing device along with the conventional Implantable Cardioverter Defibrillator (ICD) and/or Pacemaker to improve the coordination of the heart rhythm.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the cardiac resynchronisation therapy devices market within New Zealand was expected to be over $3m in 2022.
For the latest complete market share analysis of cardiac resynchronisation therapy device market in New Zealand, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
